Log in to search using one of your social media accounts:

 

​Trial fail for Cambridge-based Sage casts doubt on lead drug

Sage Therapeutics reported Tuesday morning that its drug to treat a severe and life-threatening form of epilepsy failed to meet the main goal of a late-stage trial. As of 6:50 a.m. Tuesday, Sage's shares were down 24 percent. If the drop holds until stocks open at 9:30 it would shave nearly $1 billion off the company's market capitalization. Cambridge-based Sage (Nasdaq: SAGE), which had 135 employees as of February, was testing its lead drug, called rexanol one, plus the current standard treatments…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Authors: Rodriguez AS, Engel T, Palfi A, Farrar GJ, Henshall DC, Jimenez-Mateos EM Abstract MicroRNAs are important determinants of gene expression via post-transcriptional control of the protein levels of their mRNA targets. MicroRNA-134 (miR-134) has emerged as an important brain-specific microRNA which has been implicated in the control of dendritic spine morphology, neuronal differentiation and apoptosis. Here we show that Tubby-like protein 1 (Tulp1) is a target of miR-134. Tulp1 protein showed a similar cellular distribution pattern in the hippocampus to miR-134 and displayed an inverse expression pattern in ...
Source: International Journal of Physiology, Pathophysiology and Pharmacology - Category: Physiology Tags: Int J Physiol Pathophysiol Pharmacol Source Type: research
In this study, we analyzed the value of epilepsy and other prognostic factors on GBMs survival. We retrospectively analyzed the clinical, radiological, surgical and histological data in 139 GBMs. Seizures were the presenting symptoms in 50 patients out of 139 (35.9%). 123 patients (88%) were treated with craniotomy and tumor resection while 16 (12%) with biopsy. The median overall survival was 9.9 months from surgery. At univariable Cox regression, the factors that significantly improved survival were age less than 65 years (P = 0.0015), focal without impairment of consciousness seizures at presentation (P = 0.043), comple...
Source: Neurologia Medico-Chirurgica - Category: Neurosurgery Tags: Neurol Med Chir (Tokyo) Source Type: research
This study categorizes the spectrum of MRI findings in patients with a clinical diagnosis of autoimmune epilepsy and elevated serum GAD65 autoantibodies.MethodsAn institutional database search identified patients with elevated serum GAD65 antibodies and a clinical diagnosis of autoimmune epilepsy who had undergone brain MRI. Imaging studies were reviewed by three board-certified neuroradiologists and one neuroradiology fellow. Studies were evaluated for cortical/subcortical and hippocampal signal abnormality, cerebellar and cerebral volume loss, mesial temporal sclerosis, and parenchymal/leptomeningeal enhancement. The ele...
Source: Neuroradiology - Category: Radiology Source Type: research
Authors: Huang Y, Liu X, Liao Y, Liao Y, Zou D, Wei X, Huang Q, Wu Y Abstract Studies suggest that microRNA (miR)‑34c may serve a role in cognitive function in rodent and primate groups. A previous study demonstrated an increase in miR‑34c expression in chronic epileptic rats with memory disorders, induced by pentylenetetrazol (PTZ). However, the mechanism underlying the effects of miR‑34c on cognitive function in epileptic rats remains unclear. Therefore, the present study investigated alterations in cognitive function in temporal lobe epileptic rats, induced by repeated injections of PTZ, following treatmen...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
[Image from unsplash.com]Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving medical device companies last year. The companies raking in the VC cash are doing everything from creating robotic microsurgery for the eyes to building better dialysis machines to bringing neuromodulation to bear on epilepsy. Read on to discover which medtech com...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Funding Roundup Hospital Care Implants mHealth (Mobile Health) Advanced Cardiac Therapeutics Inc. Auris Surgical Robotics Cereve EarLens Ebb Therapeutics EBR Systems Inc. Fractyl Laboratories immusant MedTech Mox Source Type: news
Condition:   Refractory Epilepsy Intervention:   Other: Questionnaires Sponsors:   University Hospital, Ghent;   Medtronic Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Epilepsy;   Epilepsy Intractable Intervention:   Other: Probiotic Sponsor:   María Gómez Eguílaz Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Refractory Epilepsy Intervention:   Other: Questionnaires Sponsors:   University Hospital, Ghent;   Medtronic Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Epilepsy;   Epilepsy Intractable Intervention:   Other: Probiotic Sponsor:   María Gómez Eguílaz Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study aimed to investigate the incidence of aggressiveness in patients with severe drug-refractory focal epilepsy (DRE) who started perampanel (PER) as add-on treatment, and to identify possible predisposing factors. Data on 49 consecutive patients with severe DRE who initiated PER were retrospectively collected. Twelve of the 49 patients experienced aggressiveness as adverse event related to PER treatment, one third of them on low (2-4 mg/day) PER dosages. PER was discontinued in 10/12 patients because of aggressive behaviors. Aggressiveness could appear after several months or even more than one year of PER treatmen...
Source: Functional Neurology - Category: Neurology Tags: Funct Neurol Source Type: research
More News: Epilepsy | Health Management | Pharmaceuticals